Five-year clinical outcomes of drug-eluting stents according to on-label and off-label use |
Park, Kyu-Hwan
(Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center)
Kim, Ung (Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center) Lee, Chan-Hee (Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center) Son, Jang-Won (Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center) Park, Jong-Seon (Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center) Shin, Dong-Gu (Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center) Kim, Young-Jo (Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center) Cho, Jeong-Hwan (Division of Cardiology, Department of Internal Medicine, Daegu Veterans Hospital) |
1 | Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997. DOI |
2 | Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323. DOI |
3 | Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008. DOI |
4 | Kimura T, Morimoto T, Nakagawa Y, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012;125:584-591. DOI |
5 | Roy P, Buch AN, Javaid A, et al. Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008;101:293-299. DOI |
6 | Qasim A, Cosgrave J, Latib A, Colombo A. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications. Am J Cardiol 2007;100:1619-1624. DOI |
7 | Poorhosseini H, Kassaian SE, Aghajani H, et al. On-label and off-label use of drug-eluting stents: comparison of short- and long-term outcomes. Tex Heart Inst J 2012;39:24-29. |
8 | Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-2009. DOI |
9 | Brodie BR, Stuckey T, Downey W, et al. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group. JACC Cardiovasc Interv 2008;1:405-414. DOI |
10 | Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-662. DOI |
11 | Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231. DOI |
12 | Food and Drug Administration. Resolute integrity zotarolimus coronary stent system [Internet]. Silver Spring (MD): Food and Drug Administration, 2015 [cited 2015 Dec 4]. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf11/p110013S005a.pdf. |
13 | Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:e574-e651. DOI |
14 | Singh M, Gersh BJ, McClelland RL, et al. Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 2005;45:198-203. DOI |
15 | Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351. DOI |
16 | Kotani J, Ikari Y, Kyo E, Nakamura M, Yokoi H. Long-term outcomes following off-label use of sirolimus-eluting stent. J Cardiol 2013;62:151-157. DOI |
17 | Bauer T, Nienaber CA, Akin I, et al. Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: results from the German DES. DE-Registry. Clin Res Cardiol 2011;100:701-709. DOI |
18 | Galasso G, Piccolo R, Cassese S, et al. Unrestricted use of endeavor resolute zotarolimus-eluting stent in daily clinical practice: a prospective registry. J Invasive Cardiol 2012;24:251-255. |
19 | Gilbert J, Raboud J, Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 2004;27:990-994. DOI |
20 | Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-146. DOI |
![]() |